【摘要】 目的探讨急性白血病（acute leukemia,AL）获得完全缓解（complete remission,CR）后检测微小残留病（minimal residual disease,MRD）的临床意义。方法所有患者初诊时均进行骨髓免疫分型检测,从首次诱导缓解治疗结束后第14天开始,每3个月检测一次MRD,并动态监测,同时进行骨髓形态学检查。结果 MRD <10^-4复发率为22.2%,MRD> 10^-3复发率为77.8%,MRD> 10^-2复发率为100%。结论经过20例患者的MRD检测显示:MRD <10^-4的复发率低,MRD﹥10^-3的复发率高,MRD﹥10^-2提示近期复发。因此,MRD对早期复发的判断、及早干预治疗和治疗方案的选择有着明显的指导意义。更多还原

【Abstract】 Objective To investigate the clinical significance of detecting microresidual disease（ MRD） after complete remission of acute leukemia（ AL）. method All patients were tested for bone marrow immunotyping at the first consultation. From the 14 th day after the first induced remission treatment,MRD was tested every 3 months,and dynamically monitored. Bone marrow morphology was also performed. Results MRD < 10^-4 relapse rate of 27 %,MRD > 10^-3 recurrence rate is 82 %,MRD > 10^-2 The relapse rate of is 100%. Conclusion The MRD test of 20 patients showed that the recurrence rate of MRD < 10^-4 was low,the recurrence rate of MRD > 10^-3 was high,and MRD > 10^-2 suggested a recent recurrence. Therefore,early diagnosis,early intervention treatment and treatment options have obvious guiding significance.更多还原